{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T17:14:06Z","timestamp":1786468446233,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015895","name":"GRIFFIN HOSPITAL","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102830","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T12:27:04Z","timestamp":1612960024000},"page":"102830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis"],"prefix":"10.1016","volume":"50","author":[{"given":"J.B.","family":"Guarnaccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ayettey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Treu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Comerford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.Y.","family":"Njike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2021.102830_bib0001","unstructured":"Anon 2020 https:\/\/en.wikipedia.org\/wiki\/List_of_2020_United_States_cannabis_reform_proposals."},{"issue":"6","key":"10.1016\/j.msard.2021.102830_bib0002","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/00952990.2019.1569668","article-title":"Time trends in U.S. cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings","volume":"45","author":"Hasin","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.msard.2021.102830_bib0003","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/add.14031","article-title":"Trends and age, period and cohort effects for marijuana use prevalence in the 1984 to 2015 US National Alcohol Surveys","volume":"113","author":"Kerr","year":"2018","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.msard.2021.102830_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.dhjo.2013.01.007","article-title":"Recent trends in substance abuse among persons with disabilities compared to that of persons without disabilities","volume":"6","author":"Glazier","year":"2013","journal-title":"Disabil Health J"},{"issue":"11","key":"10.1016\/j.msard.2021.102830_bib0005","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1212\/01.WNL.0000127707.07621.72","article-title":"Patterns of cannabis use among patients with multiple sclerosis","volume":"62","author":"Clark","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.102830_bib0006","first-page":"5","article-title":"Illegal cannabis use is common among Danes with multiple sclerosis","volume":"33","author":"Gustavsen","year":"2019","journal-title":"MultSclerRelatDisord"},{"key":"10.1016\/j.msard.2021.102830_bib0007","first-page":"123","article-title":"Attitudes to cannabis and patterns of use among Canadians with multiple sclerosis","volume":"10","author":"Banwell","year":"2016","journal-title":"MultSclerRelatDisord"},{"issue":"1-2","key":"10.1016\/j.msard.2021.102830_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2008.06.037","article-title":"Cannabis use in Spanish patients with multiple sclerosis: fulfilment of patients' expectations?","volume":"273","author":"Mart\u00ednez-Rodr\u00edguez","year":"2008","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.msard.2021.102830_bib0009","first-page":"646","article-title":"Cannabis use in patients with multiple sclerosis","volume":"12","author":"Chong","year":"2006","journal-title":"MultScler"},{"issue":"3","key":"10.1016\/j.msard.2021.102830_bib0010","first-page":"291","article-title":"The medicinal use of cannabis in the UK: results of a nationwide survey","volume":"59","author":"Ware","year":"2005","journal-title":"Int J ClinPract"},{"issue":"2","key":"10.1016\/j.msard.2021.102830_bib0011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.7224\/1537-2073.2017-112","article-title":"Marijuana Use by Patients with Multiple Sclerosis","volume":"21","author":"Gupta","year":"2019","journal-title":"Int J MS Care"},{"issue":"1","key":"10.1016\/j.msard.2021.102830_bib0012","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000112901","article-title":"The perceived effects of smoked cannabis on patients with multiple sclerosis","volume":"38","author":"Consroe","year":"1997","journal-title":"Eur Neurol"},{"key":"10.1016\/j.msard.2021.102830_bib0013","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/BF00314410","article-title":"Effect of cannabinoids on spasticity and ataxia in multiple sclerosis","volume":"236","author":"Meinck","year":"1989","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.msard.2021.102830_bib0014","first-page":"8","article-title":"The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews","volume":"18","author":"Nielsen","year":"2018","journal-title":"CurrNeurolNeurosci Rep"},{"key":"10.1016\/j.msard.2021.102830_bib0015","first-page":"383","article-title":"Exploring cannabis use by patients with multiple sclerosis in a state where cannabis is legal","volume":"27","author":"Weinkle","year":"2019","journal-title":"MultSclerRelatDisord"},{"key":"10.1016\/j.msard.2021.102830_bib0016","first-page":"50","article-title":"Cannabinoids for Treatment of MS Symptoms: State of the Evidence","volume":"18","author":"Rice","year":"2018","journal-title":"CurrNeurolNeurosci Rep"},{"issue":"3","key":"10.1016\/j.msard.2021.102830_bib0017","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.msard.2021.102830_bib0018","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1136\/jnnp-2012-302468","article-title":"Multiple sclerosis and extract of cannabis: results of the MUSEC trial","volume":"83","author":"Kondrad","year":"2012","journal-title":"J NeurolNeurosurg Psychiatry"},{"issue":"9395","key":"10.1016\/j.msard.2021.102830_bib0019","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentrerandomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2021.102830_bib0020","first-page":"324","article-title":"Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers","volume":"55","author":"Greenberg","year":"1994","journal-title":"ClinPharmacolTher"},{"issue":"4","key":"10.1016\/j.msard.2021.102830_bib0021","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1017\/S0033291713001438","article-title":"The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies","volume":"44","author":"Lev-Ran","year":"2014","journal-title":"Psychol Med"},{"issue":"11","key":"10.1016\/j.msard.2021.102830_bib0022","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1046\/j.1360-0443.2003.00437.x","article-title":"Exploring the association between cannabis use and depression","volume":"98","author":"Degenhardt","year":"2003","journal-title":"Addiction"},{"issue":"7","key":"10.1016\/j.msard.2021.102830_bib0023","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/hup.1048","article-title":"Cannabis and anxiety: a critical review of the evidence","volume":"24","author":"Crippa","year":"2009","journal-title":"Hum Psychopharmacol"},{"issue":"40","key":"10.1016\/j.msard.2021.102830_bib0024","article-title":"Persistent cannabis users show neuropsychological decline from childhood to midlife","volume":"109","author":"Meier","year":"2012","journal-title":"Proc Natl AcadSci U S A"},{"issue":"16","key":"10.1016\/j.msard.2021.102830_bib0025","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.1523\/JNEUROSCI.4745-13.2014","article-title":"Cannabis use is quantitatively associated with nucleus accumbens and amygdala abnormalities in young adult recreational users","volume":"34","author":"Gilman","year":"2014","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.msard.2021.102830_bib0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00415-017-8715-5","article-title":"Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis","volume":"265","author":"Brenton","year":"2018","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.msard.2021.102830_bib0027","first-page":"333-343","article-title":"Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants","volume":"7","author":"Cofield","year":"2017","journal-title":"NeurolClinPract"},{"key":"10.1016\/j.msard.2021.102830_bib0028","unstructured":"Anon 2020 https:\/\/portal.ct.gov\/DCP\/Medical-Marijuana-Program\/Medical -Marijuana-Statistics."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821000961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:55:28Z","timestamp":1761900928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821000961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":28,"alternative-id":["S2211034821000961"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102830","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patterns of Medical Cannabis Use among Patients Diagnosed with Multiple Sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102830"}}